GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,485.60p
   
  • Change Today:
      24.60p
  • 52 Week High: 2,263.00
  • 52 Week Low: 1,296.00
  • Currency: UK Pounds
  • Shares Issued: 4,094.68m
  • Volume: 7,774,368
  • Market Cap: £60,831m
  • RiskGrade: 129

GSK starts moves to pull FDA approval for blood cancer drug

By Frank Prenesti

Date: Tuesday 22 Nov 2022

LONDON (ShareCast) - (Sharecast News) - British pharmaceutical giant GSK on Tuesday said it has started proceedings to pull US approval for its blood cancer drug Blenrep after it failed to meet the requirements of a late-stage trial.
GSK earlier in November said Blenrep had failed to demonstrate it was more effective than a rival treatment in the market. However, the company maintained that the drug's benefit-risk profile "remains favourable in this hard-to-treat patient population".

"Patients responding to belantamab mafodotin-blmf experienced durable clinical benefit, and safety remains consistent with the known safety profile," it said in a statement.

"We respect the Agency's approach to the accelerated approval regulations and associated process. Multiple myeloma is a challenging disease, with poor outcomes for patients whose disease has become resistant to standard-of-care treatments," said Sabine Luik, GSK chief medical officer.

"We will continue the clinical trial programme and work with the US FDA on a path forward for this important treatment option for patients with multiple myeloma."

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,485.60p
Change Today 24.60p
% Change 1.68 %
52 Week High 2,263.00
52 Week Low 1,296.00
Volume 7,774,368
Shares Issued 4,094.68m
Market Cap £60,831m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average58.29% below the market average
82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average82.76% above the sector average
Price Trend
40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average40.31% below the market average
25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average25.81% above the sector average
Income
67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average67.69% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average51.89% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average

What The Brokers Say

Strong Buy 2
Buy 6
Neutral 14
Sell 1
Strong Sell 2
Total 25
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 23-Feb-23 17-Nov-22
Paid 13-Apr-23 12-Jan-23
Amount 13.75p 13.75p

Trades for 07-Feb-2023

Time Volume / Share Price
16:45 153 @ 1,485.40p
16:45 153 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:45 6,466 @ 1,485.40p
16:35 1,000 @ 1,485.60p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page